Arrowhead Receives Regulatory Clearance for ARC-AAT Phase 1 in the United Kingdom and New Zealand
July 08 2015 - 7:30AM
Business Wire
Arrowhead Research Corporation (NASDAQ: ARWR), a
biopharmaceutical company developing targeted RNAi therapeutics,
today announced that it received regulatory permission in the
United Kingdom and New Zealand to proceed with Part B of its Phase
1 study of ARC-AAT, Arrowhead’s RNAi-based drug candidate for the
treatment of liver disease associated with the rare genetic
disorder alpha-1 antitrypsin deficiency (AATD). The Phase 1 study
is currently enrolling patients at a single center in Australia
and, pending approval from ethics committees, the company intends
to begin recruiting patients at additional sites in the United
Kingdom and New Zealand. Arrowhead expects to complete enrollment
by the end of 2015.
The ongoing Phase 1 trial of ARC-AAT is a multi-center,
randomized, placebo-controlled, double-blind, single
dose-escalation, first-in-human study to evaluate the safety,
tolerability and pharmacokinetics of ARC-AAT and the effect on
circulating AAT levels. The study has been enrolling in dose
cohorts of six participants each, with participants randomized at a
ratio of 2:1 (active:placebo) to receive a single intravenous
injection of either ARC-AAT or placebo (normal saline). The study
consists of two parts; Part A in healthy volunteers, which has been
completed, and Part B to be conducted in patients with PiZZ
genotype AATD. Dosing in patients begins at the highest dose level
used in healthy volunteers and then continued dose escalation may
proceed under the protocol. The study evaluates participants for 28
days following dosing, with additional follow-up if needed every 2
weeks until AAT levels return to baseline.
About ARC-AAT
Arrowhead’s ARC-AAT is being investigated for the treatment of
liver disease associated with Alpha-1 Antitrypsin Deficiency
(AATD), a rare genetic disease that severely damages the liver and
lungs of affected individuals. The mean estimated prevalence of
AATD in the U.S is 1 per 3000-5000, or approximately 100,000
patients. AATD is also an important cause of pediatric liver
disease with an estimated prevalence in children of approximately
20,000 patients, and 50-80% likely to manifest liver disease during
childhood. It is a rare disease that appears to be frequently
misdiagnosed or undiagnosed. ARC-AAT, which was granted orphan drug
designation, employs a novel unlocked nucleobase analog (UNA)
containing RNAi trigger molecule designed for systemic delivery
using the Dynamic Polyconjugate™ delivery system. ARC-AAT is highly
effective at knocking down the Alpha-1 antitrypsin (AAT) gene
transcript and reducing the hepatic production of the mutant AAT
(Z-AAT) protein in animals. Reduction of liver production of the
inflammatory Z-AAT protein, which is believed to be the cause of
progressive liver disease in AATD patients, is important as it is
expected to halt the progression of liver disease and potentially
allow fibrotic tissue repair. Arrowhead is conducting a single dose
Phase 1 clinical study of ARC-AAT, with part A in healthy
volunteers and part B in AATD patients.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company
developing targeted RNAi therapeutics. The company is leveraging
its proprietary Dynamic Polyconjugate™ delivery platform to develop
targeted drugs based on the RNA interference mechanism that
efficiently silences disease-causing genes. Arrowhead’s pipeline
includes ARC-520 for chronic hepatitis B virus and ARC-AAT for
liver disease associated with Alpha-1 antitrypsin deficiency.
For more information please visit
http://www.arrowheadresearch.com, or follow us on Twitter
@ArrowRes. To be added to the Company's email list and receive news
directly, please visit
http://ir.arrowheadresearch.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation
Reform Act:
This news release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our
actual results may differ materially and adversely from those
expressed in any forward-looking statements as a result of various
factors and uncertainties, including our ability to finance our
operations, the future success of our scientific studies, our
ability to successfully develop drug candidates, the timing for
starting and completing clinical trials, rapid technological change
in our markets, and the enforcement of our intellectual property
rights. Arrowhead Research Corporation's most recent Annual Report
on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss
some of the important risk factors that may affect our business,
results of operations and financial condition. We assume no
obligation to update or revise forward-looking statements to
reflect new events or circumstances.
DYNAMIC POLYCONJUGATES is a trademark of Arrowhead
Research Corporation.
Source: Arrowhead Research Corporation
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150708005472/en/
Arrowhead Research CorporationVince Anzalone,
CFA626-304-3400ir@arrowres.comorInvestor Relations:The Trout
GroupTodd James646-378-2926ir@arrowres.comorMedia:Russo
PartnersMatt Middleman,
M.D.212-845-4272matt.middleman@russopartnersllc.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Apr 2023 to Apr 2024